A Comparative Study of Risperidone and Aripiprazole in Attention Deficit Hyperactivity Disorder in Children Under Six Years Old: A Randomized Double-Blind Study

Razjouyan, Katayoon; Danesh, Arash; Khademi, Mojgan; Davari-Ashtiani, Rozita; Noorbakhsh, Simasadat

doi:10.5812/ijp.60087

Cited by 7 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Risperidone group was better than the placebo group. The results of this research were not consistent with the results of other studies (34,37,38).…”

Section: Discussioncontrasting

confidence: 99%

“…A few percents of each group suffered the side-effects that only sleepiness can be observed in the group treated with Risperidone; sleepiness and vomiting, and in placebo group, sleepiness and headache were observed in group treated with Aripiprazole. In a study, the most common side-effect was nausea, vomiting and confusion in Risperidone group, and increasing apetite and sleepiness in Aripiprazole group (34) and in the other study ,there was no clear side-effect in the group treated with Aripiprazole and weight gain was observed in a group treated with Risperidone (35). In the studies conducted by Lamberti et.al (2016), and Safavi et.al (2016), prolactin level is decreased in the group treated with Aripiprazole and increased in the group treated with Risperidone, although there was no side-effect in this study (36,37).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparing the Effectiveness of Risperidone with Aripiprazole as a Combination Therapy in Attention-Deficit Hyperactivity Children with Oppositional Defiant Disorder

Yousefi

Gheshlagh

Moghadam

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: This study intends to compare the effectiveness of Risperidone with Aripiprazole as a combination therapy in Attention-deficit hyperactivity (ADHD) children with oppositional defiant disorder, treated with Methylphenidate. Methods: This is a double-blind clinical experiment. The sample size was determined as 60 (40 for the intervention group and 20 for the control group) by random sampling. The data collecting instrument was Parent's ADHD Rating Scale, Clinical Global Impression-Severity (CGI-S), demographic information checklist, and drug's side-effects checklist for this study. Repeated measurement multivariate analysis was used as a statistical method to compare the quantitative variables in both intervention and control groups using SPSS18 software. Results: The results of this study indicated that there is a substantial difference between scores in ADHD and oppositional defiant disorder (ODD) groups after 8 weeks (F=2.34, p>0.03). Conclusion: Based on the results of the present study, Aripiprazole in combination with Methylphenidate have a higher effect on reducing ADHD and ODD symptom.Trial registration: IRCT20160530028182N5; Registered 6 February 2018, https://en.irct.ir/trial/22916

show abstract

“…The Risperidone group was better than the placebo group. The results of this research were not consistent with the results of other studies (34,37,38).…”

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparing the Effectiveness of Risperidone with Aripiprazole as a Combination Therapy in Attention-Deficit Hyperactivity Children with Oppositional Defiant Disorder

Yousefi

Gheshlagh

Moghadam

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, after the 12th week, the ADHD-RS score was significantly lower when participants were treated with aripiprazole. in another study, results showed risperidone and aripiprazole are also effective in children under six years 24 .…”

Section: Discussionmentioning

confidence: 91%

Efficacy of Aripiprazole and Risperidone in Treatment of Children With Attention-Deficit/Hyperactivity Disorder: A Double-Blind Clinical Trial Study

Dreakhshanpour

Deylamsalehi

Moghadda

et al. 2022

Bulletin of Pharmaceutical Sciences. Assiut

View full text Add to dashboard Cite

Attention-deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children. Poor academic readiness for school entry, fine motor skills, and social impairment are more common in preschoolers than healthy controls. Since dopaminergic system dysfunction is connected with numerous neuropsychological diseases, including ADHD, antipsychotic drugs are used for the treatment of ADHD. Considering the importance of ADHD treatment in preschoolers and the fact that psychostimulant drugs are less effective in preschoolers and have more adverse effects, this study is conducted to compare the safety and efficacy of risperidone and aripiprazole in the treatment of ADHD. Fifty-five 3-6-year-old children diagnosed with ADHD were randomized to a 12-week trial of treatment with risperidone or aripiprazole 1 . The assessment was performed by Parent ADHD-RS, Strengths and Difficulties Questionnaire (SDQ), Children's Global Assessment Scale (CGAS) before treatment, and weeks 2, 4, 6, and 12 of treatment. The study showed that the ADHD-RS score of both groups was significantly reduced after starting the treatment. After the 12th week, the score of aripiprazole's group was significantly less than the score of risperidone's group (pvalue = 0.019). In addition, the CGAS scores and the total SDQ score improved for both groups without any statistically significant difference between them. Both risperidone and aripiprazole are effective in the treatment of ADHD among preschool-aged children. Both drugs are welltolerated, significantly reduce the ADHD-RS score and the total SDQ score and improve the CGAS score.

show abstract

“… Navari et al (2020) 30 (15 olanzapine, 15 placebo) Cancer 39–79 RCT 5 mg/d olanzapine/placebo 7 days Appetite NRS Baseline to day 7 appetite increase in the treatment group compared to placebo (d: 1.34). Razjouyan et al (2018) 48 (25 risperidone, 23 aripiprazole) ADHD 3–6 RCT Initial dose 0.25 mg/d, maximum dose 1 mg/d risperidone & initial dose 1.25 mg/d maximum dose 5 mg/d aripiprazole/placebo 12 weeks Appetite Reported -Appetite increase in the aripiprazole group (# 4, 20%). -Appetite increase in the risperidone group (# 1, 5%).…”

Section: Resultsmentioning

confidence: 99%

Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis

Mutwalli¹,

Keeler²,

Bektas³

et al. 2023

Journal of Psychiatric Research

View full text Add to dashboard Cite

A Comparative Study of Risperidone and Aripiprazole in Attention Deficit Hyperactivity Disorder in Children Under Six Years Old: A Randomized Double-Blind Study

Cited by 7 publications

References 17 publications

Comparing the Effectiveness of Risperidone with Aripiprazole as a Combination Therapy in Attention-Deficit Hyperactivity Children with Oppositional Defiant Disorder

Comparing the Effectiveness of Risperidone with Aripiprazole as a Combination Therapy in Attention-Deficit Hyperactivity Children with Oppositional Defiant Disorder

Efficacy of Aripiprazole and Risperidone in Treatment of Children With Attention-Deficit/Hyperactivity Disorder: A Double-Blind Clinical Trial Study

Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis

Contact Info

Product

Resources

About